Anchor Capital Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% in the fourth quarter, HoldingsChannel reports. The firm owned 148,525 shares of the company’s stock after selling 3,111 shares during the period. Anchor Capital Advisors LLC’s holdings in Johnson & Johnson were worth $30,737,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. CIBC Asset Management Inc boosted its stake in Johnson & Johnson by 33.6% during the 4th quarter. CIBC Asset Management Inc now owns 967,659 shares of the company’s stock valued at $200,230,000 after purchasing an additional 243,369 shares during the period. Marble Wealth LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $2,950,000. Mccarter Private Wealth Services LLC lifted its stake in shares of Johnson & Johnson by 18.1% in the 4th quarter. Mccarter Private Wealth Services LLC now owns 5,522 shares of the company’s stock worth $1,143,000 after acquiring an additional 845 shares during the period. Greenwich Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 9.4% in the 4th quarter. Greenwich Wealth Management LLC now owns 4,416 shares of the company’s stock worth $914,000 after acquiring an additional 378 shares during the period. Finally, Peak Retirement Planning Inc. lifted its stake in shares of Johnson & Johnson by 1.1% in the 4th quarter. Peak Retirement Planning Inc. now owns 11,442 shares of the company’s stock worth $2,368,000 after acquiring an additional 130 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms recently commented on JNJ. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Johnson Rice upgraded shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Argus upped their price target on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Finally, Bank of America upped their price target on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $253.04.
Trending Headlines about Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: CNBC’s Jim Cramer pointed to Johnson & Johnson as one of five stocks to buy for diversification outside the AI trade, which could attract investors looking for lower-volatility, defensive exposure. Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
- Positive Sentiment: Scotiabank reiterated its Buy rating on Johnson & Johnson, reinforcing Wall Street confidence in the company’s earnings durability and dividend appeal. Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
- Positive Sentiment: Several articles highlighted JNJ as one of the best dividend-paying stocks to own, which can support the stock as investors favor income and defensive healthcare names. Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?
- Neutral Sentiment: Recent commentary also questioned whether Johnson & Johnson’s strong one-year rally leaves limited upside near current levels, suggesting valuation could temper enthusiasm. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?
- Neutral Sentiment: A Motley Fool piece argued JNJ’s effort to challenge AbbVie’s growth driver should not alarm AbbVie shareholders, implying the competitive angle is not a major near-term negative for Johnson & Johnson itself. Johnson & Johnson Hopes to Dethrone AbbVie’s Biggest Growth Driver. Here’s Why Investors Shouldn’t Panic
Johnson & Johnson Stock Performance
Shares of JNJ opened at $223.00 on Wednesday. The company’s fifty day moving average is $232.75 and its 200-day moving average is $225.29. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The firm has a market cap of $536.81 billion, a price-to-earnings ratio of 25.78, a price-to-earnings-growth ratio of 2.19 and a beta of 0.26. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the prior year, the business posted $2.77 EPS. Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is 61.97%.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More
- Five stocks we like better than Johnson & Johnson
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
